Polymer Microencapsulation and Insilico Study Approach of Celecoxib for the Management of Alzheimer’s Disease.

Abstract

Introduction: The study investigates the impact of microencapsulation on the physicochemical properties of Celecoxib (CXB) when combined with polymers. This process aimed to enhance the dissolution rate and solubility of CXB, which is particularly evident in the ME-2 formulation.

Objective: The primary goal was to determine whether microencapsulation could improve CXB's solubility and dissolution rate, potentially offering benefits for the management of neurodegenerative disorders. Further computational studies like Molecular Docking and Binding affinity study of celecoxib with AD related proteins to assess whether CXB is a potent drug for the management of AD.

Method: The solvent evaporation technique was employed to microencapsulate CXB with various polymers. The resulting formulations were then analyzed for changes in solubility and dissolution rates. The molecular docking study was done using AutoDock vina to identify the interaction of celecoxib with selected AD protein targets in selected active sites.

Results: Microencapsulation produced micronized particles, leading to a higher dissolution rate than pure CXB. The ME-2 formulation showed the most significant improvement. SEM analysis confirmed changes in particle shape and size post-microencapsulation, while DSC tests indicated that CXB was in an amorphous state. FTIR spectra suggested the formation of hydrogen bonds between CXB and the polymers, which could account for the increased solubility. Additionally, molecular docking studies suggested that CXB has the potential to combat neurodegeneration due to its binding energy with related proteins.

Conclusion: Microencapsulation of CXB significantly enhances its solubility and permeability, which may be beneficial in treating neurodegenerative diseases. The findings support the potential of microencapsulated CXB as a therapeutic agent, with further animal studies recommended to evaluate its efficacy in managing Alzheimer's Disease (AD).